XML 1111 R95.htm IDEA: XBRL DOCUMENT v2.4.0.6
NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details) (USD $)
 9 Months Ended 1 Months Ended
Sep. 30, 2012
Dec. 31, 2011
Sep. 30, 2011
Dec. 31, 2010
Dec. 31, 2009
Dec. 31, 2008
Nov. 30, 2012
Subsequent event
Nature of Operations              
Cash and cash equivalents $ 17,837,000 $ 24,449,000 $ 27,675,000 $ 29,495,000 $ 11,493,000 $ 24,220,000  
Period for which cash and cash equivalents are sufficient to meet anticipated short-term working capital needs and to fund our on-going sapacitabine clinical trials 12 months            
NATURE OF OPERATIONS AND BASIS OF PRESENTATION              
Grant awarded from UK Government's Biomedical Catalyst             $ 1,900,000